Kunal N Bhatt1, Javed Butler2. 1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, 1365 Clifton Road NE, Atlanta, GA, 30322, USA. kunal.nikhil.bhatt@emory.edu. 2. Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
Abstract
PURPOSE OF REVIEW: Several novel therapeutics being tested in patients with heart failure are based on myocardial energetics. This review will provide a summary of the recent trials in this area, including therapeutic options targeting various aspects of cellular and mitochondrial metabolism. RECENT FINDINGS: Agents that improve the energetic balance in myocardial cells have the potential to improve clinical heart failure status. The most promising therapies currently under investigation in this arena include (1) elamipretide, a cardiolipin stabilizer; (2) repletion of iron deficiency with intravenous ferrous carboxymaltose; (3) coenzyme Q10; and (4) the partial adenosine receptor antagonists capadenoson and neladenosone. Myocardial energetics-based therapeutics are groundbreaking in that they utilize novel mechanisms of action to improve heart failure symptoms, without causing the adverse neurohormonal side effects associated with current guideline-based therapies. The drugs appear likely to be added to the heart failure therapy armamentarium as adjuncts to current regimens in the near future.
PURPOSE OF REVIEW: Several novel therapeutics being tested in patients with heart failure are based on myocardial energetics. This review will provide a summary of the recent trials in this area, including therapeutic options targeting various aspects of cellular and mitochondrial metabolism. RECENT FINDINGS: Agents that improve the energetic balance in myocardial cells have the potential to improve clinical heart failure status. The most promising therapies currently under investigation in this arena include (1) elamipretide, a cardiolipin stabilizer; (2) repletion of iron deficiency with intravenous ferrous carboxymaltose; (3) coenzyme Q10; and (4) the partial adenosine receptor antagonists capadenoson and neladenosone. Myocardial energetics-based therapeutics are groundbreaking in that they utilize novel mechanisms of action to improve heart failure symptoms, without causing the adverse neurohormonal side effects associated with current guideline-based therapies. The drugs appear likely to be added to the heart failure therapy armamentarium as adjuncts to current regimens in the near future.
Authors: Kenneth A Ellenbogen; Gearoid O'Neill; Eric N Prystowsky; John A Camm; Lixin Meng; Hsiao Dee Lieu; Markus Jerling; Revati Shreeniwas; Luiz Belardinelli; Andrew A Wolff Journal: Circulation Date: 2005-06-13 Impact factor: 29.690
Authors: William C Stanley; Eric E Morgan; Hazel Huang; Tracy A McElfresh; Joseph P Sterk; Isidore C Okere; Margaret P Chandler; Jiefei Cheng; Jason R B Dyck; Gary D Lopaschuk Journal: Am J Physiol Heart Circ Physiol Date: 2005-08-12 Impact factor: 4.733
Authors: Nicole Ebner; Ewa A Jankowska; Piotr Ponikowski; Mitja Lainscak; Sebastian Elsner; Veronika Sliziuk; Lisa Steinbeck; Jennifer Kube; Tarek Bekfani; Nadja Scherbakov; Miroslava Valentova; Anja Sandek; Wolfram Doehner; Jochen Springer; Stefan D Anker; Stephan von Haehling Journal: Int J Cardiol Date: 2015-12-02 Impact factor: 4.164
Authors: David A Brown; Justin B Perry; Mitchell E Allen; Hani N Sabbah; Brian L Stauffer; Saame Raza Shaikh; John G F Cleland; Wilson S Colucci; Javed Butler; Adriaan A Voors; Stefan D Anker; Bertram Pitt; Burkert Pieske; Gerasimos Filippatos; Stephen J Greene; Mihai Gheorghiade Journal: Nat Rev Cardiol Date: 2016-12-22 Impact factor: 32.419
Authors: Janet Pierce; John B Hiebert; Diane Mahoney; Qiuhua Shen; Jill Peltzer; Faith Rahman; Samantha Johnson; John T Pierce Journal: Ann Med Surg (Lond) Date: 2019-04-05